 OpGen, Inc. Nasdaq: OPGN, OpGen, a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that total revenue for the first quarter of 2020 was approximately 617,000 down from 1.0 million in the first quarter of 2019, excluding revenues from the Curetis businesses, which was acquired upon closing of the business combination on April 1, 2020. OpGen expects that its submission to the U.S. Food and Drug Administration FDA for clearance of the Acuitas AMR Gene Panel Isolates for the detection of antimicrobial resistance genes in bacterial isolates is nearing completion. 